Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19152985 | 0.77 | KDM4E (0.38) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL11984543 | 0.74 | POLB (0.35) | POLBOPRK1RXFP1LMNAHTT | |
| SCHEMBL883077 | 0.72 | ALDH1A1 (0.42) | HRH3HTTKDM4EALDH1A1MAPT | |
| SCHEMBL19131796 | 0.72 | HPGD (0.35) | POLBRXFP1LMNAKDM4EALDH1A1 | |
| SCHEMBL18237942 | 0.72 | TSHR (0.39) | GABRG2GABRB3GABRA5LMNAHTT | |
| SCHEMBL10286507 | 0.72 | GABRG2 (0.36) | GABRG2GABRB3GABRA5HRH3LMNA | |
| SCHEMBL12464831 | 0.69 | OPRK1 (0.38) | POLBOPRK1RXFP1LMNAHTT | |
| SCHEMBL10286088 | 0.69 | HTR2A (0.35) | GABRG2GABRB3GABRA5LMNAKDM4E | |
| SCHEMBL10286541 | 0.67 | HSD17B1 (0.33) | RXFP1HRH3LMNAHTTKDM4E | |
| SCHEMBL526812 | 0.66 | SMN1; SMN2 (0.39) | RXFP1GABRG2GABRB3GABRA5LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190290771-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2019-09-26 | — | — | US | disclosed |
| WO-2016183359-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190290771-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | POLB 3269/4885OPRK1 4295/4885RXFP1 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.